All In Biotech

Investigational drug · Phase 3

Mosliciguat

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

4

Any phase or sponsor naming "Mosliciguat"

First trial start

2024

Oct 29, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Mosliciguat", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Pulmonary Hypertension
  • Interstitial Lung Disease
  • Vascular Diseases
  • Cardiovascular Diseases
  • Fibrosis
  • Lung Diseases

Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Mosliciguat" as an intervention, largest first.

All trials
  • Pulmovant, Inc.Industry

    NCT07816185 · 376 participants (planned) · Start Aug 31, 2026 · Primary completion Jan 28, 2029

    Drug: Mosliciguat; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease; Vascular Diseases and 2 more

    Sites: Kissimmee, Florida; Louisville, Kentucky; Bend, Oregon

  • A Study of Mosliciguat in PH-ILDPivotal-lookingActive, not recruiting

    Pulmovant, Inc.Industry

    NCT06635850 · 135 participants · Start Oct 29, 2024 · Primary completion May 26, 2026

    Drug: Mosliciguat; Placebo · For: Pulmonary Hypertension; Interstitial Lung Disease; Lung Diseases and 3 more

    Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 85 sites in all

  • Pulmovant, Inc.Industry

    NCT07333183 · 20 participants (planned) · Start Dec 23, 2025 · Primary completion Dec 2026

    Drug: inhaled mosliciguat · For: Pulmonary Hypertension; Interstitial Lung Disease (ILD); Lung Diseases and 3 more

    Sites: Santa Barbara, California; Torrance, California; Kissimmee, Florida · 13 sites in all

  • Pulmovant, Inc.Industry

    NCT07185321 · 8 participants · Start Jun 10, 2025 · Primary completion Jun 30, 2025

    Drug: Mosliciguat; 14C mosliciguat · For: Healthy Volunteer

    Sites: Baltimore, Maryland

Newest research

PubMed records naming it or its code names, newest first.

All 5 on PubMed

Also in development for Pulmonary Hypertension

  • INS1009Treprostinil PalmitilPhase 37 trials

    Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension

  • TNX-103Phase 33 trials

    Tenax Therapeutics, Inc. · Pulmonary Hypertension Associated With HFpEF, Pulmonary Hypertension

  • RalinepagAPD811Phase 32 trials

    United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension

  • HS235Phase 22 trials

    35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction

  • TX000045Phase 22 trials

    Tectonic Therapeutic · Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction, Hypertension, Pulmonary

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.